Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Biomarker-Driven Trial of Oral Digoxin in Individuals With Amyotrophic Lateral Sclerosis (ALS) - The Acacia Trial, an ALS MyMatch Trial

NCT07047209 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT07047209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07047209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Biomarker-Driven Trial of Oral Digoxin in Individuals With Amyotrophic Lateral Sclerosis (ALS) - The Acacia Trial, an ALS MyMatch Trial
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Completed
Start date
May 27, 2025
Completion date
May 13, 2026
Enrollment
41 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

als (amyotrophic lateral sclerosis)